{"filing":{"accession_number":"0001193125-26-259703","cik":"0001095981","ticker":"PSTV","company_name":"PLUS THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"pstv-20260601.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1095981/000119312526259703/pstv-20260601.htm"},"events":[{"id":6507,"run_id":5694,"accession_number":"0001193125-26-259703","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Plus Therapeutics entered into an Equity Distribution Agreement with Canaccord Genuity to conduct an at-the-market (ATM) offering of up to $17,350,000 in common stock. This is a dilutive equity issuance under an ATM arrangement, which is a classic signal of capital raising at small- and mid-cap issuers. The company intends to use net proceeds for general corporate purposes and working capital, indicating potential financial stress or liquidity needs.","company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","filing_date":"2026-06-05","form":"8-K","submitted_at":null,"items":[{"id":4865,"accession_number":"0001193125-26-259703","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Plus Therapeutics entered into an Equity Distribution Agreement with Canaccord Genuity to conduct an at-the-market (ATM) offering of up to $17,350,000 in common stock. This is a dilutive equity issuance under an ATM arrangement, which is a classic signal of capital raising at small- and mid-cap issuers. The company intends to use net proceeds for general corporate purposes and working capital, indicating potential financial stress or liquidity needs.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:33:06.044357+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4865,"accession_number":"0001193125-26-259703","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Plus Therapeutics entered into an Equity Distribution Agreement with Canaccord Genuity to conduct an at-the-market (ATM) offering of up to $17,350,000 in common stock. This is a dilutive equity issuance under an ATM arrangement, which is a classic signal of capital raising at small- and mid-cap issuers. The company intends to use net proceeds for general corporate purposes and working capital, indicating potential financial stress or liquidity needs.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:33:06.044357+00:00","company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","filing_date":"2026-06-05"}]}